CA2262693A1 - Pressure sensitive adhesive matrix patches for transdermal delivery of salts of pharmaceutical agents - Google Patents
Pressure sensitive adhesive matrix patches for transdermal delivery of salts of pharmaceutical agents Download PDFInfo
- Publication number
- CA2262693A1 CA2262693A1 CA002262693A CA2262693A CA2262693A1 CA 2262693 A1 CA2262693 A1 CA 2262693A1 CA 002262693 A CA002262693 A CA 002262693A CA 2262693 A CA2262693 A CA 2262693A CA 2262693 A1 CA2262693 A1 CA 2262693A1
- Authority
- CA
- Canada
- Prior art keywords
- hcl
- drug
- pressure sensitive
- adhesive
- matrix
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000011159 matrix material Substances 0.000 title claims abstract description 90
- 150000003839 salts Chemical class 0.000 title claims abstract description 60
- 239000004820 Pressure-sensitive adhesive Substances 0.000 title claims description 46
- 230000037317 transdermal delivery Effects 0.000 title description 15
- 239000008177 pharmaceutical agent Substances 0.000 title description 9
- 239000003814 drug Substances 0.000 claims abstract description 113
- 229940079593 drug Drugs 0.000 claims abstract description 110
- 239000000853 adhesive Substances 0.000 claims abstract description 78
- 230000001070 adhesive effect Effects 0.000 claims abstract description 78
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 46
- 238000000034 method Methods 0.000 claims abstract description 40
- 230000002209 hydrophobic effect Effects 0.000 claims abstract description 24
- 239000003961 penetration enhancing agent Substances 0.000 claims abstract description 18
- QWCRAEMEVRGPNT-UHFFFAOYSA-N buspirone Chemical compound C1C(=O)N(CCCCN2CCN(CC2)C=2N=CC=CN=2)C(=O)CC21CCCC2 QWCRAEMEVRGPNT-UHFFFAOYSA-N 0.000 claims description 25
- 229960002495 buspirone Drugs 0.000 claims description 21
- 150000001875 compounds Chemical class 0.000 claims description 20
- 230000004907 flux Effects 0.000 claims description 20
- 239000000203 mixture Substances 0.000 claims description 18
- 229960002896 clonidine Drugs 0.000 claims description 16
- JGMJQSFLQWGYMQ-UHFFFAOYSA-M sodium;2,6-dichloro-n-phenylaniline;acetate Chemical compound [Na+].CC([O-])=O.ClC1=CC=CC(Cl)=C1NC1=CC=CC=C1 JGMJQSFLQWGYMQ-UHFFFAOYSA-M 0.000 claims description 16
- GJSURZIOUXUGAL-UHFFFAOYSA-N Clonidine Chemical compound ClC1=CC=CC(Cl)=C1NC1=NCCN1 GJSURZIOUXUGAL-UHFFFAOYSA-N 0.000 claims description 15
- 229960001193 diclofenac sodium Drugs 0.000 claims description 15
- 239000002904 solvent Substances 0.000 claims description 15
- 229920002367 Polyisobutene Polymers 0.000 claims description 12
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 8
- 239000003522 acrylic cement Substances 0.000 claims description 8
- 229960004384 ketorolac tromethamine Drugs 0.000 claims description 8
- BWHLPLXXIDYSNW-UHFFFAOYSA-N ketorolac tromethamine Chemical compound OCC(N)(CO)CO.OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1 BWHLPLXXIDYSNW-UHFFFAOYSA-N 0.000 claims description 8
- YECIFGHRMFEPJK-UHFFFAOYSA-N lidocaine hydrochloride monohydrate Chemical compound O.[Cl-].CC[NH+](CC)CC(=O)NC1=C(C)C=CC=C1C YECIFGHRMFEPJK-UHFFFAOYSA-N 0.000 claims description 7
- 230000002378 acidificating effect Effects 0.000 claims description 6
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims description 6
- 239000006185 dispersion Substances 0.000 claims description 6
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims description 3
- 238000005266 casting Methods 0.000 claims description 3
- KWGRBVOPPLSCSI-WPRPVWTQSA-N (-)-ephedrine Chemical compound CN[C@@H](C)[C@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WPRPVWTQSA-N 0.000 claims description 2
- YLXIPWWIOISBDD-NDAAPVSOSA-N (2r,3r)-2,3-dihydroxybutanedioic acid;4-[(1r)-1-hydroxy-2-(methylamino)ethyl]benzene-1,2-diol Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O.CNC[C@H](O)C1=CC=C(O)C(O)=C1 YLXIPWWIOISBDD-NDAAPVSOSA-N 0.000 claims description 2
- MAUPDHMFNIUWSK-UHFFFAOYSA-N 1-(1h-indol-4-yloxy)-3-(propan-2-ylamino)propan-2-ol;hydrochloride Chemical compound Cl.CC(C)NCC(O)COC1=CC=CC2=C1C=CN2 MAUPDHMFNIUWSK-UHFFFAOYSA-N 0.000 claims description 2
- JSXBVMKACNEMKY-UHFFFAOYSA-N 8-chloro-6-(4-methylpiperazin-1-yl)benzo[b][1,4]benzoxazepine;hydron;chloride Chemical compound Cl.C1CN(C)CCN1C1=NC2=CC=CC=C2OC2=CC=C(Cl)C=C12 JSXBVMKACNEMKY-UHFFFAOYSA-N 0.000 claims description 2
- DBAKFASWICGISY-BTJKTKAUSA-N Chlorpheniramine maleate Chemical compound OC(=O)\C=C/C(O)=O.C=1C=CC=NC=1C(CCN(C)C)C1=CC=C(Cl)C=C1 DBAKFASWICGISY-BTJKTKAUSA-N 0.000 claims description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims description 2
- MKXZASYAUGDDCJ-SZMVWBNQSA-N LSM-2525 Chemical compound C1CCC[C@H]2[C@@]3([H])N(C)CC[C@]21C1=CC(OC)=CC=C1C3 MKXZASYAUGDDCJ-SZMVWBNQSA-N 0.000 claims description 2
- RGHAZVBIOOEVQX-UHFFFAOYSA-N Metoprolol succinate Chemical compound OC(=O)CCC(O)=O.COCCC1=CC=C(OCC(O)CNC(C)C)C=C1.COCCC1=CC=C(OCC(O)CNC(C)C)C=C1 RGHAZVBIOOEVQX-UHFFFAOYSA-N 0.000 claims description 2
- UBDNTYUBJLXUNN-IFLJXUKPSA-N Oxytetracycline hydrochloride Chemical compound Cl.C1=CC=C2[C@](O)(C)[C@H]3[C@H](O)[C@H]4[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O UBDNTYUBJLXUNN-IFLJXUKPSA-N 0.000 claims description 2
- GFBKORZTTCHDGY-UWVJOHFNSA-N Thiothixene Chemical compound C12=CC(S(=O)(=O)N(C)C)=CC=C2SC2=CC=CC=C2\C1=C\CCN1CCN(C)CC1 GFBKORZTTCHDGY-UWVJOHFNSA-N 0.000 claims description 2
- HOBWAPHTEJGALG-JKCMADFCSA-N [(1r,5s)-8-methyl-8-azoniabicyclo[3.2.1]octan-3-yl] 3-hydroxy-2-phenylpropanoate;sulfate Chemical compound [O-]S([O-])(=O)=O.C([C@H]1CC[C@@H](C2)[NH+]1C)C2OC(=O)C(CO)C1=CC=CC=C1.C([C@H]1CC[C@@H](C2)[NH+]1C)C2OC(=O)C(CO)C1=CC=CC=C1 HOBWAPHTEJGALG-JKCMADFCSA-N 0.000 claims description 2
- 229960002576 amiloride Drugs 0.000 claims description 2
- XSDQTOBWRPYKKA-UHFFFAOYSA-N amiloride Chemical compound NC(=N)NC(=O)C1=NC(Cl)=C(N)N=C1N XSDQTOBWRPYKKA-UHFFFAOYSA-N 0.000 claims description 2
- KLOHDWPABZXLGI-YWUHCJSESA-M ampicillin sodium Chemical compound [Na+].C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C([O-])=O)(C)C)=CC=CC=C1 KLOHDWPABZXLGI-YWUHCJSESA-M 0.000 claims description 2
- VMWNQDUVQKEIOC-CYBMUJFWSA-N apomorphine Chemical compound C([C@H]1N(C)CC2)C3=CC=C(O)C(O)=C3C3=C1C2=CC=C3 VMWNQDUVQKEIOC-CYBMUJFWSA-N 0.000 claims description 2
- 229960004046 apomorphine Drugs 0.000 claims description 2
- 229960002028 atropine sulfate Drugs 0.000 claims description 2
- SRGKFVAASLQVBO-BTJKTKAUSA-N brompheniramine maleate Chemical compound OC(=O)\C=C/C(O)=O.C=1C=CC=NC=1C(CCN(C)C)C1=CC=C(Br)C=C1 SRGKFVAASLQVBO-BTJKTKAUSA-N 0.000 claims description 2
- 229960003108 brompheniramine maleate Drugs 0.000 claims description 2
- XMEVHPAGJVLHIG-FMZCEJRJSA-N chembl454950 Chemical compound [Cl-].C1=CC=C2[C@](O)(C)[C@H]3C[C@H]4[C@H]([NH+](C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O XMEVHPAGJVLHIG-FMZCEJRJSA-N 0.000 claims description 2
- 229940046978 chlorpheniramine maleate Drugs 0.000 claims description 2
- IVHBBMHQKZBJEU-UHFFFAOYSA-N cinchocaine hydrochloride Chemical compound [Cl-].C1=CC=CC2=NC(OCCCC)=CC(C(=O)NCC[NH+](CC)CC)=C21 IVHBBMHQKZBJEU-UHFFFAOYSA-N 0.000 claims description 2
- 229960000265 cromoglicic acid Drugs 0.000 claims description 2
- 229960001985 dextromethorphan Drugs 0.000 claims description 2
- KPHWPUGNDIVLNH-UHFFFAOYSA-M diclofenac sodium Chemical compound [Na+].[O-]C(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl KPHWPUGNDIVLNH-UHFFFAOYSA-M 0.000 claims description 2
- VLARUOGDXDTHEH-UHFFFAOYSA-L disodium cromoglycate Chemical compound [Na+].[Na+].O1C(C([O-])=O)=CC(=O)C2=C1C=CC=C2OCC(O)COC1=CC=CC2=C1C(=O)C=C(C([O-])=O)O2 VLARUOGDXDTHEH-UHFFFAOYSA-L 0.000 claims description 2
- 229960002179 ephedrine Drugs 0.000 claims description 2
- 229960003157 epinephrine bitartrate Drugs 0.000 claims description 2
- 238000001704 evaporation Methods 0.000 claims description 2
- 229960004207 fentanyl citrate Drugs 0.000 claims description 2
- IVLVTNPOHDFFCJ-UHFFFAOYSA-N fentanyl citrate Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.C=1C=CC=CC=1N(C(=O)CC)C(CC1)CCN1CCC1=CC=CC=C1 IVLVTNPOHDFFCJ-UHFFFAOYSA-N 0.000 claims description 2
- 229940050411 fumarate Drugs 0.000 claims description 2
- 229960000939 metoprolol succinate Drugs 0.000 claims description 2
- 229960001300 metoprolol tartrate Drugs 0.000 claims description 2
- 238000002156 mixing Methods 0.000 claims description 2
- NETZHAKZCGBWSS-CEDHKZHLSA-N nalbuphine Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]1(O)CC[C@@H]3O)CN2CC1CCC1 NETZHAKZCGBWSS-CEDHKZHLSA-N 0.000 claims description 2
- 229960000805 nalbuphine Drugs 0.000 claims description 2
- UZHSEJADLWPNLE-GRGSLBFTSA-N naloxone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(O)C2=C5[C@@]13CCN4CC=C UZHSEJADLWPNLE-GRGSLBFTSA-N 0.000 claims description 2
- 229960004127 naloxone Drugs 0.000 claims description 2
- DQCKKXVULJGBQN-XFWGSAIBSA-N naltrexone Chemical compound N1([C@@H]2CC3=CC=C(C=4O[C@@H]5[C@](C3=4)([C@]2(CCC5=O)O)CC1)O)CC1CC1 DQCKKXVULJGBQN-XFWGSAIBSA-N 0.000 claims description 2
- 229960003086 naltrexone Drugs 0.000 claims description 2
- 229960001802 phenylephrine Drugs 0.000 claims description 2
- SONNWYBIRXJNDC-VIFPVBQESA-N phenylephrine Chemical compound CNC[C@H](O)C1=CC=CC(O)=C1 SONNWYBIRXJNDC-VIFPVBQESA-N 0.000 claims description 2
- 229960000395 phenylpropanolamine Drugs 0.000 claims description 2
- DLNKOYKMWOXYQA-APPZFPTMSA-N phenylpropanolamine Chemical compound C[C@@H](N)[C@H](O)C1=CC=CC=C1 DLNKOYKMWOXYQA-APPZFPTMSA-N 0.000 claims description 2
- 229960003712 propranolol Drugs 0.000 claims description 2
- AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 claims description 2
- LACQPOBCQQPVIT-SEYKEWMNSA-N scopolamine hydrobromide trihydrate Chemical compound O.O.O.Br.C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 LACQPOBCQQPVIT-SEYKEWMNSA-N 0.000 claims description 2
- RMLUKZWYIKEASN-UHFFFAOYSA-M sodium;2-amino-9-(2-hydroxyethoxymethyl)purin-6-olate Chemical compound [Na+].O=C1[N-]C(N)=NC2=C1N=CN2COCCO RMLUKZWYIKEASN-UHFFFAOYSA-M 0.000 claims description 2
- KFVSLSTULZVNPG-UHFFFAOYSA-N terbutaline sulfate Chemical compound [O-]S([O-])(=O)=O.CC(C)(C)[NH2+]CC(O)C1=CC(O)=CC(O)=C1.CC(C)(C)[NH2+]CC(O)C1=CC(O)=CC(O)=C1 KFVSLSTULZVNPG-UHFFFAOYSA-N 0.000 claims description 2
- 229960005105 terbutaline sulfate Drugs 0.000 claims description 2
- WUBVEMGCQRSBBT-UHFFFAOYSA-N tert-butyl 4-(trifluoromethylsulfonyloxy)-3,6-dihydro-2h-pyridine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC(OS(=O)(=O)C(F)(F)F)=CC1 WUBVEMGCQRSBBT-UHFFFAOYSA-N 0.000 claims description 2
- 229960002372 tetracaine Drugs 0.000 claims description 2
- GKCBAIGFKIBETG-UHFFFAOYSA-N tetracaine Chemical compound CCCCNC1=CC=C(C(=O)OCCN(C)C)C=C1 GKCBAIGFKIBETG-UHFFFAOYSA-N 0.000 claims description 2
- 229960002180 tetracycline Drugs 0.000 claims description 2
- 229960005013 tiotixene Drugs 0.000 claims description 2
- 229960002312 tolazoline Drugs 0.000 claims description 2
- JIVZKJJQOZQXQB-UHFFFAOYSA-N tolazoline Chemical compound C=1C=CC=CC=1CC1=NCCN1 JIVZKJJQOZQXQB-UHFFFAOYSA-N 0.000 claims description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 2
- 229940057282 albuterol sulfate Drugs 0.000 claims 1
- BNPSSFBOAGDEEL-UHFFFAOYSA-N albuterol sulfate Chemical compound OS(O)(=O)=O.CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1.CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 BNPSSFBOAGDEEL-UHFFFAOYSA-N 0.000 claims 1
- 238000002425 crystallisation Methods 0.000 claims 1
- 230000008025 crystallization Effects 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 238000010030 laminating Methods 0.000 claims 1
- 210000003491 skin Anatomy 0.000 description 45
- 239000003960 organic solvent Substances 0.000 description 35
- 239000010410 layer Substances 0.000 description 26
- 239000012458 free base Substances 0.000 description 23
- 239000002253 acid Substances 0.000 description 19
- 238000000338 in vitro Methods 0.000 description 16
- 210000004027 cell Anatomy 0.000 description 14
- 239000003623 enhancer Substances 0.000 description 13
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 description 11
- OZWKMVRBQXNZKK-UHFFFAOYSA-N ketorolac Chemical compound OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1 OZWKMVRBQXNZKK-UHFFFAOYSA-N 0.000 description 11
- 239000013078 crystal Substances 0.000 description 10
- 238000002474 experimental method Methods 0.000 description 10
- 239000007787 solid Substances 0.000 description 10
- 229960004752 ketorolac Drugs 0.000 description 9
- 239000000463 material Substances 0.000 description 9
- -1 polysiloxanes Polymers 0.000 description 9
- 210000004927 skin cell Anatomy 0.000 description 9
- 229960001259 diclofenac Drugs 0.000 description 8
- 239000010408 film Substances 0.000 description 8
- 239000002585 base Substances 0.000 description 7
- 150000003840 hydrochlorides Chemical class 0.000 description 7
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 6
- 238000009792 diffusion process Methods 0.000 description 6
- 239000000839 emulsion Substances 0.000 description 6
- 239000012528 membrane Substances 0.000 description 6
- 239000012942 water-based acrylic adhesive Substances 0.000 description 6
- QQQMUBLXDAFBRH-UHFFFAOYSA-N dodecyl 2-hydroxypropanoate Chemical compound CCCCCCCCCCCCOC(=O)C(C)O QQQMUBLXDAFBRH-UHFFFAOYSA-N 0.000 description 5
- 229920000642 polymer Polymers 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 5
- 239000013543 active substance Substances 0.000 description 4
- 229940088679 drug related substance Drugs 0.000 description 4
- 210000004877 mucosa Anatomy 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- 210000000434 stratum corneum Anatomy 0.000 description 4
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 102100038968 WAP four-disulfide core domain protein 1 Human genes 0.000 description 3
- 239000008186 active pharmaceutical agent Substances 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000010348 incorporation Methods 0.000 description 3
- 229960004194 lidocaine Drugs 0.000 description 3
- 229960002715 nicotine Drugs 0.000 description 3
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 3
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 159000000000 sodium salts Chemical class 0.000 description 3
- 229940127291 Calcium channel antagonist Drugs 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 2
- 239000004698 Polyethylene Substances 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- GCSPRLPXTPMSTL-IBDNADADSA-N [(2s,3r,4s,5s,6r)-2-[(2s,3s,4s,5r)-3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl] dodecanoate Chemical compound CCCCCCCCCCCC(=O)O[C@@]1([C@]2(CO)[C@H]([C@H](O)[C@@H](CO)O2)O)O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O GCSPRLPXTPMSTL-IBDNADADSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 2
- 229910052782 aluminium Inorganic materials 0.000 description 2
- 229940035676 analgesics Drugs 0.000 description 2
- 239000000730 antalgic agent Substances 0.000 description 2
- 239000002220 antihypertensive agent Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 239000000480 calcium channel blocker Substances 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000000812 cholinergic antagonist Substances 0.000 description 2
- 239000002131 composite material Substances 0.000 description 2
- 210000004207 dermis Anatomy 0.000 description 2
- ILRSCQWREDREME-UHFFFAOYSA-N dodecanamide Chemical compound CCCCCCCCCCCC(N)=O ILRSCQWREDREME-UHFFFAOYSA-N 0.000 description 2
- 238000012377 drug delivery Methods 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- UQDUPQYQJKYHQI-UHFFFAOYSA-N methyl laurate Chemical compound CCCCCCCCCCCC(=O)OC UQDUPQYQJKYHQI-UHFFFAOYSA-N 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 2
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 230000035515 penetration Effects 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 229920000191 poly(N-vinyl pyrrolidone) Polymers 0.000 description 2
- 229920000058 polyacrylate Polymers 0.000 description 2
- 229920000728 polyester Polymers 0.000 description 2
- 229920000573 polyethylene Polymers 0.000 description 2
- 229920001296 polysiloxane Polymers 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 229960002646 scopolamine Drugs 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical class OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 description 1
- WDQFELCEOPFLCZ-UHFFFAOYSA-N 1-(2-hydroxyethyl)pyrrolidin-2-one Chemical compound OCCN1CCCC1=O WDQFELCEOPFLCZ-UHFFFAOYSA-N 0.000 description 1
- AXTGDCSMTYGJND-UHFFFAOYSA-N 1-dodecylazepan-2-one Chemical compound CCCCCCCCCCCCN1CCCCCC1=O AXTGDCSMTYGJND-UHFFFAOYSA-N 0.000 description 1
- ARIWANIATODDMH-AWEZNQCLSA-N 1-lauroyl-sn-glycerol Chemical compound CCCCCCCCCCCC(=O)OC[C@@H](O)CO ARIWANIATODDMH-AWEZNQCLSA-N 0.000 description 1
- RZRNAYUHWVFMIP-KTKRTIGZSA-N 1-oleoylglycerol Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(O)CO RZRNAYUHWVFMIP-KTKRTIGZSA-N 0.000 description 1
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- FDVCQFAKOKLXGE-UHFFFAOYSA-N 216978-79-9 Chemical compound C1CC(C)(C)C2=CC(C=O)=CC3=C2N1CCC3(C)C FDVCQFAKOKLXGE-UHFFFAOYSA-N 0.000 description 1
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
- XZIIFPSPUDAGJM-UHFFFAOYSA-N 6-chloro-2-n,2-n-diethylpyrimidine-2,4-diamine Chemical compound CCN(CC)C1=NC(N)=CC(Cl)=N1 XZIIFPSPUDAGJM-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical class O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 1
- 229930000680 A04AD01 - Scopolamine Natural products 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical class CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 1
- STECJAGHUSJQJN-GAUPFVANSA-N Hyoscine Natural products C1([C@H](CO)C(=O)OC2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-GAUPFVANSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- ARIWANIATODDMH-UHFFFAOYSA-N Lauric acid monoglyceride Natural products CCCCCCCCCCCC(=O)OCC(O)CO ARIWANIATODDMH-UHFFFAOYSA-N 0.000 description 1
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 1
- STECJAGHUSJQJN-UHFFFAOYSA-N N-Methyl-scopolamin Natural products C1C(C2C3O2)N(C)C3CC1OC(=O)C(CO)C1=CC=CC=C1 STECJAGHUSJQJN-UHFFFAOYSA-N 0.000 description 1
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 description 1
- 239000000006 Nitroglycerin Substances 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 229920002614 Polyether block amide Polymers 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 229920001328 Polyvinylidene chloride Polymers 0.000 description 1
- 239000000150 Sympathomimetic Substances 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- 239000002313 adhesive film Substances 0.000 description 1
- 239000012790 adhesive layer Substances 0.000 description 1
- 239000002998 adhesive polymer Substances 0.000 description 1
- 239000002160 alpha blocker Substances 0.000 description 1
- 229940124308 alpha-adrenoreceptor antagonist Drugs 0.000 description 1
- 230000003444 anaesthetic effect Effects 0.000 description 1
- 239000002269 analeptic agent Substances 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 230000000578 anorexic effect Effects 0.000 description 1
- 230000000507 anthelmentic effect Effects 0.000 description 1
- 230000003288 anthiarrhythmic effect Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000002456 anti-arthritic effect Effects 0.000 description 1
- 230000001142 anti-diarrhea Effects 0.000 description 1
- 230000002686 anti-diuretic effect Effects 0.000 description 1
- 230000003276 anti-hypertensive effect Effects 0.000 description 1
- 230000002924 anti-infective effect Effects 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940035678 anti-parkinson drug Drugs 0.000 description 1
- 230000001139 anti-pruritic effect Effects 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 230000002921 anti-spasmodic effect Effects 0.000 description 1
- 239000003416 antiarrhythmic agent Substances 0.000 description 1
- 229940124346 antiarthritic agent Drugs 0.000 description 1
- 239000000924 antiasthmatic agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 229940065524 anticholinergics inhalants for obstructive airway diseases Drugs 0.000 description 1
- 229940125681 anticonvulsant agent Drugs 0.000 description 1
- 239000001961 anticonvulsive agent Substances 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- 229940125708 antidiabetic agent Drugs 0.000 description 1
- 229940125714 antidiarrheal agent Drugs 0.000 description 1
- 239000003793 antidiarrheal agent Substances 0.000 description 1
- 229940124538 antidiuretic agent Drugs 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 229940030600 antihypertensive agent Drugs 0.000 description 1
- 229940127088 antihypertensive drug Drugs 0.000 description 1
- 229960005475 antiinfective agent Drugs 0.000 description 1
- 229940005486 antimigraine preparations Drugs 0.000 description 1
- 239000002579 antinauseant Substances 0.000 description 1
- 239000003908 antipruritic agent Substances 0.000 description 1
- 239000000164 antipsychotic agent Substances 0.000 description 1
- 229940005529 antipsychotics Drugs 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 229940125716 antipyretic agent Drugs 0.000 description 1
- 229940124575 antispasmodic agent Drugs 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 239000002249 anxiolytic agent Substances 0.000 description 1
- 239000012062 aqueous buffer Substances 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- OGBUMNBNEWYMNJ-UHFFFAOYSA-N batilol Chemical class CCCCCCCCCCCCCCCCCCOCC(O)CO OGBUMNBNEWYMNJ-UHFFFAOYSA-N 0.000 description 1
- 239000002876 beta blocker Substances 0.000 description 1
- 229940097320 beta blocking agent Drugs 0.000 description 1
- 229910002056 binary alloy Inorganic materials 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 229920001400 block copolymer Polymers 0.000 description 1
- 230000008061 calcium-channel-blocking effect Effects 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 229940037530 cough and cold preparations Drugs 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 239000000850 decongestant Substances 0.000 description 1
- 229940124581 decongestants Drugs 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 239000007933 dermal patch Substances 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 150000002009 diols Chemical class 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 229940030606 diuretics Drugs 0.000 description 1
- LQZZUXJYWNFBMV-UHFFFAOYSA-N dodecan-1-ol Chemical compound CCCCCCCCCCCCO LQZZUXJYWNFBMV-UHFFFAOYSA-N 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000013536 elastomeric material Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 229960005309 estradiol Drugs 0.000 description 1
- 229930182833 estradiol Natural products 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- RZRNAYUHWVFMIP-HXUWFJFHSA-N glycerol monolinoleate Natural products CCCCCCCCC=CCCCCCCCC(=O)OC[C@H](O)CO RZRNAYUHWVFMIP-HXUWFJFHSA-N 0.000 description 1
- 229960003711 glyceryl trinitrate Drugs 0.000 description 1
- IXCSERBJSXMMFS-UHFFFAOYSA-N hcl hcl Chemical compound Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 150000002433 hydrophilic molecules Chemical class 0.000 description 1
- 239000003326 hypnotic agent Substances 0.000 description 1
- 230000000147 hypnotic effect Effects 0.000 description 1
- 229940125721 immunosuppressive agent Drugs 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- 229940116335 lauramide Drugs 0.000 description 1
- 150000002632 lipids Chemical group 0.000 description 1
- 229940083747 low-ceiling diuretics xanthine derivative Drugs 0.000 description 1
- 238000003760 magnetic stirring Methods 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical group OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 150000002688 maleic acid derivatives Chemical class 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 229940035363 muscle relaxants Drugs 0.000 description 1
- 239000003158 myorelaxant agent Substances 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 230000002445 parasympatholytic effect Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229920006267 polyester film Polymers 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229920002635 polyurethane Polymers 0.000 description 1
- 239000004814 polyurethane Substances 0.000 description 1
- 239000005033 polyvinylidene chloride Substances 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229960003975 potassium Drugs 0.000 description 1
- 239000003450 potassium channel blocker Substances 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 239000003368 psychostimulant agent Substances 0.000 description 1
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 235000003441 saturated fatty acids Nutrition 0.000 description 1
- 150000004671 saturated fatty acids Chemical class 0.000 description 1
- STECJAGHUSJQJN-FWXGHANASA-N scopolamine Chemical compound C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-FWXGHANASA-N 0.000 description 1
- 229940125723 sedative agent Drugs 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 231100000245 skin permeability Toxicity 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 229940035044 sorbitan monolaurate Drugs 0.000 description 1
- 239000001593 sorbitan monooleate Substances 0.000 description 1
- 229940035049 sorbitan monooleate Drugs 0.000 description 1
- 235000011069 sorbitan monooleate Nutrition 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000001975 sympathomimetic effect Effects 0.000 description 1
- 229940064707 sympathomimetics Drugs 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 239000010409 thin film Substances 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 230000002110 toxicologic effect Effects 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 239000003204 tranquilizing agent Substances 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 1
- 239000005526 vasoconstrictor agent Substances 0.000 description 1
- 229940124549 vasodilator Drugs 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F13/02—Adhesive bandages or dressings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
- A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
- A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
- A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
- A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
- A61K9/7061—Polyacrylates
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Materials For Medical Uses (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/706,624 US5985317A (en) | 1996-09-06 | 1996-09-06 | Pressure sensitive adhesive matrix patches for transdermal delivery of salts of pharmaceutical agents |
| US08/706,624 | 1996-09-06 | ||
| PCT/US1997/015302 WO1998009591A1 (en) | 1996-09-06 | 1997-08-29 | Pressure sensitive adhesive matrix patches for transdermal delivery of salts of pharmaceutical agents |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2262693A1 true CA2262693A1 (en) | 1998-03-12 |
Family
ID=24838399
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002262693A Abandoned CA2262693A1 (en) | 1996-09-06 | 1997-08-29 | Pressure sensitive adhesive matrix patches for transdermal delivery of salts of pharmaceutical agents |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US5985317A (enExample) |
| EP (1) | EP0952799A1 (enExample) |
| JP (1) | JP2000517343A (enExample) |
| KR (1) | KR20000068029A (enExample) |
| AR (1) | AR009516A1 (enExample) |
| AU (1) | AU4242797A (enExample) |
| BR (1) | BR9712806A (enExample) |
| CA (1) | CA2262693A1 (enExample) |
| NZ (1) | NZ333866A (enExample) |
| WO (1) | WO1998009591A1 (enExample) |
| ZA (1) | ZA977832B (enExample) |
Families Citing this family (232)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6365178B1 (en) * | 1996-09-06 | 2002-04-02 | Watson Pharmaceuticals, Inc. | Method of making pressure sensitive adhesive matrix patches for transdermal drug delivery using hydrophilic salts of drugs and hydrophobic pressure sensitive adhesive dispersions |
| US5800832A (en) * | 1996-10-18 | 1998-09-01 | Virotex Corporation | Bioerodable film for delivery of pharmaceutical compounds to mucosal surfaces |
| US7629384B2 (en) * | 1997-09-17 | 2009-12-08 | Strategic Science & Technologies, Llc | Topical delivery of L-arginine to cause beneficial effects |
| US20050048102A1 (en) * | 1997-10-16 | 2005-03-03 | Virotex Corporation | Pharmaceutical carrier device suitable for delivery of pharmaceutical compounds to mucosal surfaces |
| EP1117389A1 (en) * | 1998-09-08 | 2001-07-25 | TheraTech, Inc. | Method of making pressure sensitive adhesive matrix patches containing hydrophilic salts of drugs |
| GB9828480D0 (en) * | 1998-12-24 | 1999-02-17 | Dermatech Limited | Transdermal drug delivery system |
| US6562368B2 (en) | 1999-12-16 | 2003-05-13 | Dermatrends, Inc. | Transdermal administration of oxybutynin using hydroxide-releasing agents as permeation enhancers |
| US6562370B2 (en) | 1999-12-16 | 2003-05-13 | Dermatrends, Inc. | Transdermal administration of steroid drugs using hydroxide-releasing agents as permeation enhancers |
| US6582724B2 (en) * | 1999-12-16 | 2003-06-24 | Dermatrends, Inc. | Dual enhancer composition for topical and transdermal drug delivery |
| US6558695B2 (en) * | 1999-12-16 | 2003-05-06 | Dermatrends, Inc. | Topical and transdermal administration of peptidyl drugs using hydroxide releasing agents as permeation enhancers |
| US6586000B2 (en) * | 1999-12-16 | 2003-07-01 | Dermatrends, Inc. | Hydroxide-releasing agents as skin permeation enhancers |
| US6673363B2 (en) * | 1999-12-16 | 2004-01-06 | Dermatrends, Inc. | Transdermal and topical administration of local anesthetic agents using basic enhancers |
| US6719997B2 (en) | 2000-06-30 | 2004-04-13 | Dermatrends, Inc. | Transdermal administration of pharmacologically active amines using hydroxide-releasing agents as permeation enhancers |
| US20030104041A1 (en) * | 1999-12-16 | 2003-06-05 | Tsung-Min Hsu | Transdermal and topical administration of drugs using basic permeation enhancers |
| US6565879B1 (en) | 1999-12-16 | 2003-05-20 | Dermatrends, Inc. | Topical and transdermal administration of peptidyl drugs with hydroxide-releasing agents as skin permeation enhancers |
| US6645520B2 (en) | 1999-12-16 | 2003-11-11 | Dermatrends, Inc. | Transdermal administration of nonsteroidal anti-inflammatory drugs using hydroxide-releasing agents as permeation enhancers |
| US6562369B2 (en) | 1999-12-16 | 2003-05-13 | Dermatrends, Inc. | Transdermal administration of androgenic drugs hydroxide-releasing agents as permeation enhancers |
| US6602912B2 (en) | 2000-06-30 | 2003-08-05 | Dermatrends, Inc. | Transdermal administration of phenylpropanolamine |
| US7166719B2 (en) | 2002-06-27 | 2007-01-23 | Health Research, Inc. | Fluorinated photosensitizers related to chlorins and bacteriochlorins for photodynamic therapy |
| US7897140B2 (en) | 1999-12-23 | 2011-03-01 | Health Research, Inc. | Multi DTPA conjugated tetrapyrollic compounds for phototherapeutic contrast agents |
| DE10004790B4 (de) * | 2000-02-01 | 2004-09-09 | Lts Lohmann Therapie-Systeme Ag | Transdermales therapeutisches System zur Verabreichung von Zaleplon, Verfahren zu seiner Herstellung und seine Verwendung |
| US6518359B1 (en) | 2000-02-25 | 2003-02-11 | 3M Innovative Properties Co. | Polyurethane-based pressure-sensitive adhesives, systems for such adhesives, articles therefrom, and methods of making |
| US6642304B1 (en) | 2000-02-25 | 2003-11-04 | 3M Innovative Properties Company | Polyurethane-based adhesives, systems for such adhesives, articles therefrom, and methods of making |
| CN1438861A (zh) | 2000-04-26 | 2003-08-27 | 沃特森药物公司 | 最小化与奥昔布宁疗法有关的副作用 |
| US7179483B2 (en) * | 2000-04-26 | 2007-02-20 | Watson Pharmaceuticals, Inc. | Compositions and methods for transdermal oxybutynin therapy |
| US20030124177A1 (en) * | 2000-04-26 | 2003-07-03 | Watson Pharmaceuticals, Inc. | Compositions and methods for transdermal oxybutynin therapy |
| US7029694B2 (en) | 2000-04-26 | 2006-04-18 | Watson Laboratories, Inc. | Compositions and methods for transdermal oxybutynin therapy |
| US20020119187A1 (en) * | 2000-09-29 | 2002-08-29 | Cantor Adam S. | Composition for the transdermal delivery of fentanyl |
| KR100732948B1 (ko) * | 2000-11-22 | 2007-06-27 | 아이큐어 주식회사 | 국소마취용 패취 |
| US20050208117A1 (en) * | 2001-03-16 | 2005-09-22 | Venkatraman Subramanian S | Transdermal administration of fentanyl and analogs thereof |
| DE20220982U1 (de) | 2001-03-16 | 2004-11-25 | Alza Corp., Mountain View | Transdermal-Pflaster zum Verabreichen von Fentanyl |
| JP5354763B2 (ja) * | 2001-03-16 | 2013-11-27 | アルザ・コーポレーシヨン | フェンタニルを投与するための経皮的張り付け剤 |
| HUP0401022A3 (en) * | 2001-08-14 | 2006-11-28 | Biotie Therapies Corp | Method for the preparation of pharmaceutical compositions containing opioid antagonist for treating alcoholism or alcohol abuse |
| DE10141650C1 (de) | 2001-08-24 | 2002-11-28 | Lohmann Therapie Syst Lts | Transdermales Therapeutisches System mit Fentanyl bzw. verwandten Substanzen |
| EP1446110A2 (en) * | 2001-10-16 | 2004-08-18 | Structural Bioinformatics Inc. | Organosulfur inhibitors of tyrosine phosphatases |
| US20050226915A1 (en) * | 2001-12-28 | 2005-10-13 | Oramelts Corporation, A Washington Corporation | Method for manufacturing and packaging oral patches with rounded edges |
| US20030124178A1 (en) * | 2001-12-28 | 2003-07-03 | Haley Jeffrey T. | Soft, adherent, soluble oral patch |
| US7022342B2 (en) | 2002-03-28 | 2006-04-04 | Andrx Corporation, Inc. | Controlled release oral dosage form of beta-adrenergic blocking agents |
| WO2003090729A1 (en) | 2002-04-23 | 2003-11-06 | Alza Corporation | Transdermal analgesic systems with reduced abuse potential |
| US7053210B2 (en) | 2002-07-02 | 2006-05-30 | Health Research, Inc. | Efficient synthesis of pyropheophorbide a and its derivatives |
| WO2004017941A2 (en) * | 2002-08-20 | 2004-03-04 | Euro-Celtique, S.A. | Transdermal dosage form comprising an active agent and a salt and free-baseform of an antagonist |
| US20040086551A1 (en) * | 2002-10-30 | 2004-05-06 | Miller Kenneth J. | Fentanyl suspension-based silicone adhesive formulations and devices for transdermal delivery of fentanyl |
| AU2004235794B8 (en) | 2003-04-30 | 2009-07-23 | Purdue Pharma L.P. | Tamper-resistant transdermal dosage form comprising an active agent component and an adverse agent component at the distal site of the active agent layer |
| US20040219195A1 (en) * | 2003-04-30 | 2004-11-04 | 3M Innovative Properties Company | Abuse-resistant transdermal dosage form |
| US8790689B2 (en) | 2003-04-30 | 2014-07-29 | Purdue Pharma L.P. | Tamper resistant transdermal dosage form |
| US7182955B2 (en) * | 2003-04-30 | 2007-02-27 | 3M Innovative Properties Company | Abuse-resistant transdermal dosage form |
| EP1628666B1 (en) * | 2003-05-14 | 2015-09-23 | NeuroGenetic Pharmaceuticals, Inc. | Compouds and uses thereof in modulating amyloid beta |
| US20080020028A1 (en) * | 2003-08-20 | 2008-01-24 | Euro-Celtique S.A. | Transdermal dosage form comprising an active agent and a salt and a free-base form of an adverse agent |
| CN1909892A (zh) | 2003-10-30 | 2007-02-07 | 阿尔扎公司 | 具有降低的滥用可能性的透皮止痛剂系统 |
| US20050137375A1 (en) * | 2003-12-19 | 2005-06-23 | 3M Innovative Properties Company | Polyurethane-based pressure sensitive adhesives and methods of manufacture |
| WO2005090370A1 (en) | 2004-02-05 | 2005-09-29 | The Regents Of The University Of California | Pharmacologically active agents containing esterified phosphonates and methods for use thereof |
| EP1737429B1 (en) * | 2004-04-19 | 2013-07-17 | Strategic Science & Technologies, LLC | Transdermal delivery of beneficial substances effected by a high ionic strength environment |
| US9226909B2 (en) | 2004-04-19 | 2016-01-05 | Strategic Science & Technologies, Llc | Beneficial effects of increasing local blood flow |
| AU2005245470A1 (en) | 2004-05-20 | 2005-12-01 | Foldrx Pharmaceuticals, Inc. | 2-((hetero) aryl)-benzoxazole compounds and derivatives, compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding |
| US7666914B2 (en) * | 2004-06-03 | 2010-02-23 | Richlin David M | Topical preparation and method for transdermal delivery and localization of therapeutic agents |
| US20060135773A1 (en) * | 2004-06-17 | 2006-06-22 | Semple Joseph E | Trisubstituted nitrogen modulators of tyrosine phosphatases |
| WO2006017124A2 (en) * | 2004-07-09 | 2006-02-16 | Cengent Therapeutics, Inc. | Oxygen/nitrogen heterocycle inhibitors of tyrosine phosphatases |
| JP4824963B2 (ja) * | 2004-08-12 | 2011-11-30 | 日東電工株式会社 | 貼付材及び貼付製剤 |
| JP4745747B2 (ja) | 2004-08-12 | 2011-08-10 | 日東電工株式会社 | フェンタニル含有貼付製剤 |
| CN101005833A (zh) * | 2004-08-20 | 2007-07-25 | 3M创新有限公司 | 具有半透明保护膜的透皮药物递送装置 |
| EP1841749A1 (en) | 2004-09-02 | 2007-10-10 | Metabasis Therapeutics, Inc. | Derivatives of thiazole and thiadiazole inhibitors of tyrosine phosphatases |
| NZ554545A (en) | 2004-09-17 | 2010-10-29 | Whitehead Inst Of Biomedical R | Compounds, compositions and methods of inhibiting alpha-synuclein toxicity |
| US20060134201A1 (en) * | 2004-12-16 | 2006-06-22 | Haley Jeffrey T | Collagen troches for treating mouth lesions |
| TW200640526A (en) * | 2005-02-24 | 2006-12-01 | Alza Corp | Transdermal electrotransport drug delivery systems with reduced abuse potential |
| EP1866319B1 (en) | 2005-04-01 | 2011-11-23 | The Regents of The University of California | Phosphono-pent-2-en-1-yl nucleosides and analogs |
| WO2006134937A1 (ja) * | 2005-06-14 | 2006-12-21 | Sekisui Chemical Co., Ltd. | 皮膚外用剤 |
| WO2007002109A2 (en) * | 2005-06-20 | 2007-01-04 | The Regents Of The University Of California | Multidentate pyrone-derived chelators for medicinal imaging and chelation |
| US10137135B2 (en) | 2005-08-15 | 2018-11-27 | Allergan Sales, Llc | Formulations and methods for providing progestin-only contraception while minimizing adverse side effects associated therewith |
| US20080058282A1 (en) | 2005-08-30 | 2008-03-06 | Fallon Joan M | Use of lactulose in the treatment of autism |
| US8492428B2 (en) * | 2005-09-20 | 2013-07-23 | Mayo Foundation For Medical Education And Research | Small-molecule botulinum toxin inhibitors |
| WO2007035940A2 (en) * | 2005-09-23 | 2007-03-29 | Alza Corporation | Transdermal norelgestromin delivery system |
| WO2007035939A2 (en) | 2005-09-23 | 2007-03-29 | Alza Corporation | High enhancer-loading polyacrylate formulation for transdermal applications |
| WO2007035941A2 (en) * | 2005-09-23 | 2007-03-29 | Alza Corporation | Transdermal galantamine delivery system |
| US20090169602A1 (en) * | 2005-11-23 | 2009-07-02 | Universität Zürich | Allergy Treatment by Epicutaneous Allergen Administration |
| US8349120B2 (en) * | 2006-03-07 | 2013-01-08 | Ora Health Corporation | Multi-layer patch made on a sheet and enclosed in a blister |
| JP2009531443A (ja) * | 2006-03-29 | 2009-09-03 | フォールドアールエックス ファーマシューティカルズ インコーポレーティッド | α−シヌクレイン毒性の抑制 |
| DE102006019293A1 (de) * | 2006-04-21 | 2007-10-25 | LABTEC Gesellschaft für technologische Forschung und Entwicklung mbH | Pflaster, enthaltend ein Fentanyl Analogum |
| US20070248654A1 (en) * | 2006-04-21 | 2007-10-25 | Haley Jeffrey T | Protective mouth sore discs made with corn starch |
| US20070248655A1 (en) * | 2006-04-21 | 2007-10-25 | Haley Jeffrey T | Lenticular shaped protective mouth sore discs |
| SI2054031T1 (sl) | 2006-07-21 | 2016-09-30 | Biodelivery Sciences International, Inc. | Transmukozne naprave za administracijo z izboljšanim vnosom |
| EA021255B1 (ru) | 2006-08-28 | 2015-05-29 | Киова Хакко Кирин Ко., Лимитед | Антагонистические моноклональные антитела человека, специфичные в отношении light человека |
| US20080226702A1 (en) * | 2007-03-16 | 2008-09-18 | Endo Pharmaceuticals, Inc. | Transdermal Delivery Form Disposal Systems and Methods |
| US20090018154A1 (en) * | 2007-05-17 | 2009-01-15 | Endo Pharmaceuticals, Inc., A Corporation Of Delaware | Opioid and methods of making and using the same |
| US20090264421A1 (en) * | 2007-10-05 | 2009-10-22 | Bible Keith C | Methods and Compositions for Treating Cancer |
| CN101902996B (zh) | 2007-10-15 | 2014-11-26 | 阿尔扎公司 | 芬太尼的一天更换一次透皮施用 |
| JP2011504485A (ja) * | 2007-11-21 | 2011-02-10 | ファーマクシス リミテッド | Ｓｓａｏ／ｖａｐ−１のハロアリルアミン阻害剤およびその用途 |
| WO2009106831A2 (en) | 2008-02-28 | 2009-09-03 | Syntropharma Limited | Pharmaceutical composition |
| US8658163B2 (en) | 2008-03-13 | 2014-02-25 | Curemark Llc | Compositions and use thereof for treating symptoms of preeclampsia |
| US8084025B2 (en) | 2008-04-18 | 2011-12-27 | Curemark Llc | Method for the treatment of the symptoms of drug and alcohol addiction |
| EP2318035B1 (en) | 2008-07-01 | 2019-06-12 | Curemark, Llc | Methods and compositions for the treatment of symptoms of neurological and mental health disorders |
| US20100221313A1 (en) * | 2008-12-01 | 2010-09-02 | Innovative Pharmaceuticals, Llc | Transdermal reservoir patch |
| ES2668909T3 (es) | 2009-01-06 | 2018-05-23 | Galenagen, Llc | Composiciones que comprenden proteasa, amilasa y lipasa para su uso en el tratamiento de infecciones por Staphylococcus aureus |
| US9084784B2 (en) | 2009-01-06 | 2015-07-21 | Curelon Llc | Compositions and methods for the treatment or the prevention of E. coli infections and for the eradication or reduction of E. coli surfaces |
| PL2401267T3 (pl) * | 2009-02-27 | 2014-06-30 | Ambit Biosciences Corp | Pochodne chinazoliny modulujące kinazę JAK i ich zastosowanie w metodach |
| WO2010111346A2 (en) * | 2009-03-24 | 2010-09-30 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Hep-lock and iv site dry mitt |
| US9056050B2 (en) | 2009-04-13 | 2015-06-16 | Curemark Llc | Enzyme delivery systems and methods of preparation and use |
| US9463158B2 (en) | 2009-06-24 | 2016-10-11 | Strategic Science & Technologies, Llc | Treatment of erectile dysfunction and other indications |
| EP2445493A1 (en) | 2009-06-24 | 2012-05-02 | Strategic Science & Technologies, LLC | Topical composition containing naproxen |
| US12138268B2 (en) | 2009-06-24 | 2024-11-12 | Strategic Science & Technologies, Llc | Treatment of erectile dysfunction and other indications |
| CN102481275B (zh) | 2009-06-24 | 2014-07-23 | 战略科学技术有限公司 | 含有布洛芬的表面组合物 |
| US11684624B2 (en) | 2009-06-24 | 2023-06-27 | Strategic Science & Technologies, Llc | Treatment of erectile dysfunction and other indications |
| US8404728B2 (en) | 2009-07-30 | 2013-03-26 | Mayo Foundation For Medical Education And Research | Small-molecule botulinum toxin inhibitors |
| WO2011057214A2 (en) | 2009-11-09 | 2011-05-12 | Neurogenetic Pharmaceuticals, Inc. | Gamma-secretase modulatory compounds, methods for identifying same, and uses therefor |
| US20110301235A1 (en) | 2009-12-02 | 2011-12-08 | Alquest Therapeutics, Inc. | Organoselenium compounds and uses thereof |
| US8710092B2 (en) | 2009-12-23 | 2014-04-29 | Map Pharmaceuticals, Inc. | Substituted indolo 4,3 FG quinolines useful for treating migraine |
| WO2011130455A1 (en) | 2010-04-13 | 2011-10-20 | Najib Babul | Dermal pharmaceutical compositions of 1-methyl-2',6'-pipecoloxylidide and method of use |
| US9289495B2 (en) | 2010-12-29 | 2016-03-22 | Strategic Science & Technologies, Llc | Systems and methods for treatment of allergies and other indications |
| CN106310242B (zh) | 2011-04-21 | 2020-02-28 | 柯尔马克有限责任公司 | 用于治疗神经精神障碍的化合物 |
| US11786455B2 (en) | 2011-05-10 | 2023-10-17 | Itochu Chemical Frontier Corporation | Non-aqueous patch |
| BR112013028802B1 (pt) | 2011-05-10 | 2021-10-26 | Itochu Chemical Frontier Corporation | Curativo adesivo não-aquoso |
| ES3034911T3 (en) | 2011-05-10 | 2025-08-26 | Itochu Chemical Frontier Corp | Non-aqueous patch |
| JP2014517076A (ja) | 2011-06-23 | 2014-07-17 | マップ・ファーマシューティカルズ・インコーポレイテッド | 新規のフルオロエルゴリン類似体 |
| SG10201610097WA (en) | 2011-08-18 | 2017-01-27 | Biodelivery Sciences Int Inc | Abuse-resistant mucoadhesive devices for delivery of buprenorphine |
| WO2013037482A1 (en) | 2011-09-15 | 2013-03-21 | Phenex Pharmaceuticals Ag | Farnesoid x receptor agonists for cancer treatment and prevention |
| DK2823815T3 (en) | 2011-09-27 | 2018-08-06 | Itochu Chemical Frontier Corp | NON-DIFFICULT PLASTER |
| CA2790749A1 (en) * | 2011-09-29 | 2013-03-29 | Nitto Denko Corporation | Manufacturing method of patch preparation |
| SG10201509139QA (en) | 2011-12-19 | 2015-12-30 | Map Pharmaceuticals Inc | Novel iso-ergoline derivatives |
| US9901539B2 (en) | 2011-12-21 | 2018-02-27 | Biodelivery Sciences International, Inc. | Transmucosal drug delivery devices for use in chronic pain relief |
| SG10201506202RA (en) | 2011-12-21 | 2015-09-29 | Map Pharmaceuticals Inc | Novel neuromodulatory compounds |
| PT2844637T (pt) | 2012-05-02 | 2018-04-17 | Boehringer Ingelheim Int | Inibidores de 3-haloalilamina substituídos de ssao e as suas utilizações |
| US10350278B2 (en) | 2012-05-30 | 2019-07-16 | Curemark, Llc | Methods of treating Celiac disease |
| US9732038B2 (en) | 2012-06-14 | 2017-08-15 | Mayo Foundation For Medical Education And Research | Pyrazole derivatives as inhibitors of STAT3 |
| US9012640B2 (en) | 2012-06-22 | 2015-04-21 | Map Pharmaceuticals, Inc. | Cabergoline derivatives |
| US9074186B2 (en) | 2012-08-15 | 2015-07-07 | Boston Medical Center Corporation | Production of red blood cells and platelets from stem cells |
| US9364273B2 (en) * | 2012-08-15 | 2016-06-14 | DePuy Synthes Products, Inc. | Drug eluting surgical screw |
| WO2014068600A1 (en) | 2012-11-02 | 2014-05-08 | Zydus Technologies Limited | Stable transdermal pharmaceutical drug delivery system comprising diclofenac |
| CA2895829A1 (en) | 2012-12-21 | 2014-06-26 | Map Pharmaceuticals, Inc. | Novel methysergide derivatives |
| US9169214B2 (en) | 2012-12-21 | 2015-10-27 | The Board Of Trustees Of The Leland Stanford Junior University | Compounds and compositions that bind and stabilize transthyretin and their use for inhibiting transthyretin amyloidosis and protein-protein interactions |
| JP6824735B2 (ja) | 2013-06-06 | 2021-02-03 | ピエール、ファーブル、メディカマン | 抗Ｃ１０ｏｒｆ５４抗体およびその使用方法 |
| WO2014210504A1 (en) * | 2013-06-28 | 2014-12-31 | Mitroo Sumair | Tape having transdermal analgesic properties |
| GB201403775D0 (en) | 2014-03-04 | 2014-04-16 | Kymab Ltd | Antibodies, uses & methods |
| AU2015266958A1 (en) | 2014-05-28 | 2016-12-08 | Agenus Inc. | Anti-GITR antibodies and methods of use thereof |
| WO2016009064A1 (en) | 2014-07-18 | 2016-01-21 | Buzzz Pharmaceuticals Limited | Abuse deterrent opiod/opiod-antagonist transdermal patch |
| US20160045609A1 (en) | 2014-08-14 | 2016-02-18 | Mamoun M. Alhamadsheh | Conjugation of pharmaceutically active agents with transthyretin ligands through adjustable linkers to increase serum half-life |
| CA2970352A1 (en) | 2014-12-11 | 2016-06-16 | Pierre Fabre Medicament | Anti-c10orf54 antibodies and uses thereof |
| MY181540A (en) * | 2014-12-18 | 2020-12-28 | Icure Pharm Inc | Transdermal composition containing donepezil as active ingredient |
| US10221248B2 (en) | 2014-12-22 | 2019-03-05 | The Rockefeller University | Anti-MERTK agonistic antibodies and uses thereof |
| US10010543B1 (en) | 2014-12-23 | 2018-07-03 | Barr Laboratories, Inc. | Transdermal dosage form |
| WO2016118541A1 (en) | 2015-01-20 | 2016-07-28 | Xoc Pharmaceuticals, Inc | Ergoline compounds and uses thereof |
| JP2018502889A (ja) | 2015-01-20 | 2018-02-01 | エックスオーシー ファーマシューティカルズ インコーポレイテッドＸｏｃ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ | イソエルゴリン化合物およびその使用 |
| HRP20230046T1 (hr) | 2015-03-03 | 2023-03-03 | Kymab Limited | Protutijela, upotreba i postupci |
| US20180156807A1 (en) | 2015-04-29 | 2018-06-07 | New York University | Method for treating high-grade gliomas |
| SI3303394T1 (sl) | 2015-05-29 | 2020-10-30 | Agenus Inc. | Protitelesa proti-CTLA-4 in postopki njihove uporabe |
| CN114605548A (zh) | 2015-09-01 | 2022-06-10 | 艾吉纳斯公司 | 抗-pd-1抗体及其使用方法 |
| CA3006966A1 (en) | 2015-12-02 | 2017-06-08 | Astraea Therapeutics, Llc | Piperidinyl nociceptin receptor compounds |
| US10112924B2 (en) | 2015-12-02 | 2018-10-30 | Astraea Therapeutics, Inc. | Piperdinyl nociceptin receptor compounds |
| US10960013B2 (en) | 2016-03-04 | 2021-03-30 | East Carolina University | J-series prostaglandin-ethanolamides as novel therapeutics for skin and/or oral disorders |
| WO2017156191A1 (en) | 2016-03-08 | 2017-09-14 | Los Gatos Pharmaceuticals, Inc. | Composite nanoparticles and uses thereof |
| JP2019513151A (ja) | 2016-03-08 | 2019-05-23 | ロス ガトス ファーマスーティカルズ， インク．Ｌｏｓ Ｇａｔｏｓ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | カンプトテシン誘導体及びその使用 |
| US10047077B2 (en) | 2016-04-13 | 2018-08-14 | Skyline Antiinfectives, Inc. | Deuterated O-sulfated beta-lactam hydroxamic acids and deuterated N-sulfated beta-lactams |
| DK3454904T3 (da) | 2016-05-13 | 2023-02-06 | Pasteur Institut | Inhibering af beta-2-nikotiniske acetylcholinreceptorer til at behandle patologi ved Alzheimers sygdom |
| TWI781934B (zh) | 2016-05-27 | 2022-11-01 | 美商艾吉納斯公司 | 抗-tim-3抗體及其使用方法 |
| KR20190039937A (ko) | 2016-07-08 | 2019-04-16 | 스태튼 바이오테크놀로지 비.브이. | 항-ApoC3 항체 및 이의 사용 방법 |
| US10919904B2 (en) | 2016-08-17 | 2021-02-16 | North Carolina State University | Northern-southern route to synthesis of bacteriochlorins |
| TW202436356A (zh) | 2016-10-11 | 2024-09-16 | 美商艾吉納斯公司 | 抗ｌａｇ－３抗體及其使用方法 |
| US11779604B2 (en) | 2016-11-03 | 2023-10-10 | Kymab Limited | Antibodies, combinations comprising antibodies, biomarkers, uses and methods |
| KR102539159B1 (ko) | 2016-11-07 | 2023-06-02 | 주식회사 뉴라클사이언스 | 서열 유사성을 가진 항-패밀리 19, 멤버 a5 항체 및 그것의 사용 방법 |
| WO2018089692A1 (en) | 2016-11-09 | 2018-05-17 | Phloronol, Inc. | Eckol derivatives, methods of synthesis and uses thereof |
| US10836774B2 (en) | 2016-11-30 | 2020-11-17 | North Carolina State University | Methods for making bacteriochlorin macrocycles comprising an annulated isocyclic ring and related compounds |
| CN118634323A (zh) | 2016-12-07 | 2024-09-13 | 艾吉纳斯公司 | 抗体和其使用方法 |
| US11013802B2 (en) | 2016-12-07 | 2021-05-25 | Agenus Inc. | Anti-CTLA-4 antibodies and methods of use thereof |
| AU2018220515B2 (en) | 2017-02-17 | 2022-06-30 | DayLife LLC | Universal antivenom |
| CN116730921A (zh) | 2017-02-17 | 2023-09-12 | 文涵治疗有限公司 | Ag-10的制备方法、其中间体及其盐 |
| WO2018191233A1 (en) | 2017-04-10 | 2018-10-18 | Curemark, Llc | Compositions for treating addiction |
| KR102629972B1 (ko) | 2017-04-13 | 2024-01-29 | 아게누스 인코포레이티드 | 항-cd137 항체 및 이의 사용 방법 |
| CA3059133A1 (en) | 2017-04-21 | 2018-10-25 | Staten Biotechnology B.V. | Anti-apoc3 antibodies and methods of use thereof |
| US11021537B2 (en) | 2017-05-01 | 2021-06-01 | Agenus Inc. | Anti-TIGIT antibodies and methods of use thereof |
| US10085999B1 (en) | 2017-05-10 | 2018-10-02 | Arixa Pharmaceuticals, Inc. | Beta-lactamase inhibitors and uses thereof |
| MX2019014272A (es) | 2017-06-01 | 2020-12-11 | Xoc Pharmaceuticals Inc | Compuestos policiclicos y usos de los mismos. |
| WO2019002228A1 (en) | 2017-06-26 | 2019-01-03 | Institut Pasteur | TREATMENTS TO REMOVE HIV RESERVOIRS AND REDUCE VIRAL LOAD |
| EP3645039A4 (en) | 2017-06-27 | 2021-05-05 | Neuracle Science Co., Ltd | USE OF ANTI-FAM19A5 ANTIBODIES TO TREAT FIBROSIS |
| KR20220031738A (ko) | 2017-06-27 | 2022-03-11 | 주식회사 뉴라클사이언스 | 암 치료를 위한 항-fam19a5 항체의 용도 |
| EP3645044A4 (en) | 2017-06-27 | 2021-04-28 | Neuracle Science Co., Ltd | USE OF ANTI-FAMILY WITH SEQUENCE SIMILARITY 19, ELEMENT A5 ANTIBODIES TO TREAT GLAUCOMA |
| KR102905526B1 (ko) | 2017-06-27 | 2025-12-30 | 주식회사 뉴라클사이언스 | 항-fam19a5 항체 및 이의 용도 |
| ES2953032T3 (es) | 2017-09-01 | 2023-11-07 | Univ East Carolina | Métodos ex vivo para la activación de las células inmunológicas |
| WO2019069229A1 (en) | 2017-10-02 | 2019-04-11 | Neuracle Science Co., Ltd. | USE OF ANTIBODIES DIRECTED AGAINST A SIMILARITY FAMILY OF SEQUENCE 19, ELEMENT A5, FOR THE TREATMENT AND DIAGNOSIS OF MOOD DISORDERS |
| SG11202003980PA (en) | 2017-10-31 | 2020-05-28 | Staten Biotechnology B V | Anti-apoc3 antibodies and methods of use thereof |
| WO2019113470A1 (en) * | 2017-12-08 | 2019-06-13 | Teikoku Pharma Usa, Inc. | Naloxone transdermal delivery devices and methods for using the same |
| MA52137A (fr) | 2018-03-23 | 2021-01-27 | Eidos Therapeutics Inc | Méthodes de traitement de l'amylose ttr à l'aide d'ag10 |
| KR20200118913A (ko) | 2018-04-24 | 2020-10-16 | 주식회사 뉴라클사이언스 | 신경병성 통증의 치료를 위한 서열 유사성 19, 멤버 a5 항체를 갖는 항-패밀리의 용도 |
| CA3098805A1 (en) | 2018-05-10 | 2019-11-14 | Neuracle Science Co., Ltd. | Anti-family with sequence similarity 19, member a5 antibodies and method of use thereof |
| WO2020008366A1 (en) | 2018-07-02 | 2020-01-09 | Clexio Biosciences Ltd. | Transdermal dosage form |
| WO2020008370A1 (en) | 2018-07-02 | 2020-01-09 | Clexio Biosciences Ltd. | Transdermal patch |
| WO2020009685A1 (en) | 2018-07-02 | 2020-01-09 | John Tang | Transdermal dosage form |
| MA53160A (fr) | 2018-07-20 | 2021-05-26 | Pf Medicament | Récepteur pour vista |
| JP7469293B2 (ja) | 2018-08-17 | 2024-04-16 | エイドス セラピューティクス，インコーポレイティド | Ａｇ１０の製剤 |
| EP3860713A2 (en) | 2018-10-03 | 2021-08-11 | Staten Biotechnology B.V. | Antibodies specific for human and cynomolgus apoc3 and methods of use thereof |
| EP3867272A4 (en) | 2018-10-16 | 2022-08-03 | Neuracle Science Co., Ltd | USE OF ANTI-FAM19A5 ANTIBODIES |
| US20220008515A1 (en) | 2018-11-16 | 2022-01-13 | Neoimmunetech, Inc. | Method of treating a tumor with a combination of il-7 protein and an immune checkpoint inhibitor |
| WO2020118042A1 (en) | 2018-12-05 | 2020-06-11 | Jacobs Wagner Christine | Borrelia burgdorferi peptidoglycan as a diagnostic and target for therapeutic intervention of lyme disease-related pathologies |
| WO2020128033A1 (en) | 2018-12-20 | 2020-06-25 | Institut Pasteur | Cellular metabolism of hiv-1 reservoir seeding in cd4+ t cells |
| KR102757347B1 (ko) | 2018-12-27 | 2025-01-23 | 주식회사 뉴라클사이언스 | 죽상경화증을 치료하기 위한 항-fam19a5 항체의 사용 |
| CN117964756A (zh) | 2019-01-02 | 2024-05-03 | 纽洛可科学有限公司 | 抗序列相似家族19成员a5的抗体及其使用方法 |
| TWI839461B (zh) | 2019-02-06 | 2024-04-21 | 美商戴斯阿爾法股份有限公司 | Il-17a調節物及其用途 |
| CN113874081A (zh) | 2019-02-26 | 2021-12-31 | 茵思博纳公司 | 高-亲和力抗-mertk抗体及其用途 |
| WO2020236818A1 (en) | 2019-05-20 | 2020-11-26 | Nirvana Sciences Inc. | Narrow emission dyes, compositions comprising same, and methods for making and using same |
| ES3036313T3 (en) | 2019-05-20 | 2025-09-17 | Nirvana Sciences Inc | Narrow emission dyes, compositions comprising same, and methods for making and using same |
| AU2020335928A1 (en) | 2019-08-30 | 2022-02-17 | Agenus Inc. | Anti-CD96 antibodies and methods of use thereof |
| JP7566889B2 (ja) | 2019-09-16 | 2024-10-15 | ダイス・アルファ・インコーポレイテッド | Ｉｌ－１７ａモジュレーターおよびその使用 |
| JP2023512456A (ja) | 2020-01-13 | 2023-03-27 | ネオイミューンテック， インコーポレイテッド | Ｉｌ－７タンパク質と二重特異性抗体の組み合わせで腫瘍を治療する方法 |
| WO2021158783A1 (en) | 2020-02-05 | 2021-08-12 | Washington University | Method of treating a solid tumor with a combination of an il-7 protein and car-bearing immune cells |
| EP4103181A4 (en) | 2020-02-14 | 2024-03-06 | Teikoku Pharma USA, Inc. | TOPICAL NALOXONE COMPOSITION AND METHOD OF USE THEREOF |
| EP4125902A4 (en) * | 2020-03-30 | 2024-05-22 | Shinkei Therapeutics, Inc. | TRANSDERMAL ADMINISTRATION OF DEXTROMETHORPHAN |
| GB2593902B (en) | 2020-04-07 | 2022-04-13 | Actimed Therapeutics Ltd | Salt of a pharmaceutical compound |
| EP4149471A4 (en) | 2020-06-30 | 2024-07-10 | Prosetta Biosciences, Inc. | ISOQUINOLINE DERIVATIVES, PROCESSES FOR THE SYNTHESIS AND USES THEREOF |
| US11541009B2 (en) | 2020-09-10 | 2023-01-03 | Curemark, Llc | Methods of prophylaxis of coronavirus infection and treatment of coronaviruses |
| US20230398184A1 (en) | 2020-10-26 | 2023-12-14 | Neoimmunetech, Inc. | Methods of inducing stem cell mobilization |
| KR20230104176A (ko) | 2020-11-02 | 2023-07-07 | 네오이뮨텍, 인코퍼레이티드 | 코로나바이러스의 치료를 위한 인터류킨-7의 용도 |
| CA3195594A1 (en) | 2020-11-05 | 2022-05-12 | Byung Ha Lee | Method of treating a tumor with a combination of an il-7 protein and a nucleotide vaccine |
| WO2022192545A1 (en) | 2021-03-10 | 2022-09-15 | Dice Molecules Sv, Inc. | Alpha v beta 6 and alpha v beta 1 integrin inhibitors and uses thereof |
| WO2022263357A1 (en) | 2021-06-14 | 2022-12-22 | Argenx Iip Bv | Anti-il-9 antibodies and methods of use thereof |
| US12017997B2 (en) | 2021-10-22 | 2024-06-25 | Prosetta Biosciences, Inc. | Host-targeted pan-respiratory antiviral small molecule therapeutics |
| WO2023081923A1 (en) | 2021-11-08 | 2023-05-11 | Frequency Therapeutics, Inc. | Platelet-derived growth factor receptor (pdgfr) alpha inhibitors and uses thereof |
| CN119836296A (zh) | 2021-12-30 | 2025-04-15 | 新免疫技术有限公司 | 用il-7蛋白和vegf拮抗剂的组合治疗肿瘤的方法 |
| WO2023129576A2 (en) | 2022-01-03 | 2023-07-06 | Lilac Therapeutics, Inc. | Acyclic thiol prodrugs |
| WO2023129577A1 (en) | 2022-01-03 | 2023-07-06 | Lilac Therapeutics, Inc. | Cyclic thiol prodrugs |
| US12168673B2 (en) | 2022-03-02 | 2024-12-17 | Mitopower, Inc. | Prodrugs derived from nicotinic acid and ribose |
| GB2619907A (en) | 2022-04-01 | 2023-12-27 | Kanna Health Ltd | Novel crystalline salt forms of mesembrine |
| EP4604988A1 (en) | 2022-10-21 | 2025-08-27 | Diagonal Therapeutics Inc. | Heteromeric agonistic antibodies to il-18 receptor |
| WO2024102722A1 (en) | 2022-11-07 | 2024-05-16 | Neoimmunetech, Inc. | Methods of treating a tumor with an unmethylated mgmt promoter |
| WO2024194685A2 (en) | 2023-03-17 | 2024-09-26 | Oxitope Pharma B.V. | Anti-phosphocholine antibodies and methods of use thereof |
| EP4680632A2 (en) | 2023-03-17 | 2026-01-21 | Oxitope Pharma B.V. | Anti-phosphocholine antibodies and methods of use thereof |
| KR20250168499A (ko) | 2023-04-07 | 2025-12-02 | 다이애고널 테라퓨틱스 인코포레이티드 | 액티빈 a 수용체 유사 유형 1(alk1)에 대한 이중 특이적 효현성 항체 |
| AU2024254039A1 (en) | 2023-04-07 | 2025-10-02 | Diagonal Therapeutics Inc. | Hinge-modified bispecific antibodies |
| WO2024233642A1 (en) | 2023-05-09 | 2024-11-14 | Progentos Therapeutics, Inc. | Heterocyclic compounds and uses thereof |
| AU2024276812A1 (en) | 2023-05-19 | 2025-11-06 | Diagonal Therapeutics Inc. | Bispecific agonistic antibodies to il12 receptor |
| KR20260033048A (ko) | 2023-07-03 | 2026-03-10 | 네오이뮨텍, 인코퍼레이티드 | 이종이합체 fc 분자 및 이의 용도 |
| US20250101101A1 (en) | 2023-09-01 | 2025-03-27 | iTeos Belgium SA | Anti-trem2 antibodies and methods of use |
| WO2025090519A1 (en) | 2023-10-23 | 2025-05-01 | Diagonal Therapeutics Inc. | Heteromeric agonistic antibodies to il-18 receptor |
| GB2636969A (en) | 2023-11-24 | 2025-07-09 | Ontrack Therapeutics Ltd | Novel crystalline salt forms |
| WO2025133707A1 (en) | 2023-12-19 | 2025-06-26 | Vectory Therapeutics B.V. | Anti-tdp-43 antibodies and uses thereof |
| WO2025201633A1 (en) | 2024-03-26 | 2025-10-02 | Chen Gefei | An agent for reducing amyloid formation |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4262003A (en) * | 1975-12-08 | 1981-04-14 | Alza Corporation | Method and therapeutic system for administering scopolamine transdermally |
| US4201211A (en) * | 1977-07-12 | 1980-05-06 | Alza Corporation | Therapeutic system for administering clonidine transdermally |
| DE2920500A1 (de) * | 1979-05-21 | 1980-11-27 | Boehringer Sohn Ingelheim | Pharmazeutische zubereitung in form eines polyacrylatfilmes |
| US5310559A (en) * | 1982-09-01 | 1994-05-10 | Hercon Laboratories Corporation | Device for controlled release and delivery to mammalian tissue of pharmacologically active agents incorporating a rate controlling member which comprises an alkylene-alkyl acrylate copolymer |
| US4564010A (en) * | 1984-04-18 | 1986-01-14 | Daubert Coated Products Inc. | Pressure sensitive adhesive film for medical use |
| ATE59302T1 (de) * | 1984-07-24 | 1991-01-15 | Key Pharma | Klebende schicht zur transdermalen freigabe. |
| US4904475A (en) * | 1985-05-03 | 1990-02-27 | Alza Corporation | Transdermal delivery of drugs from an aqueous reservoir |
| US4645502A (en) * | 1985-05-03 | 1987-02-24 | Alza Corporation | Transdermal delivery of highly ionized fat insoluble drugs |
| US4863970A (en) * | 1986-11-14 | 1989-09-05 | Theratech, Inc. | Penetration enhancement with binary system of oleic acid, oleins, and oleyl alcohol with lower alcohols |
| US4956171A (en) * | 1989-07-21 | 1990-09-11 | Paco Pharmaceutical Services, Inc. | Transdermal drug delivery using a dual permeation enhancer and method of performing the same |
| US5002773A (en) * | 1989-09-29 | 1991-03-26 | Marion Merrell Dow Inc. | Transdermal delivery of (+) (2S,3S)-3-acetoxy-8-chloro-5-(2-dimethylaminoethyl)-2,3-dihydro-2-(4-methoxyphenyl)-1,5-benzothiazepin-4-(5H)-one |
| US5230896A (en) * | 1989-10-12 | 1993-07-27 | Warner-Lambert Company | Transdermal nicotine delivery system |
| US5633009A (en) * | 1990-11-28 | 1997-05-27 | Sano Corporation | Transdermal administration of azapirones |
| JP2849950B2 (ja) * | 1990-11-30 | 1999-01-27 | 日東電工株式会社 | 経皮吸収製剤 |
| US5149538A (en) * | 1991-06-14 | 1992-09-22 | Warner-Lambert Company | Misuse-resistive transdermal opioid dosage form |
| US5883115A (en) * | 1992-11-09 | 1999-03-16 | Pharmetrix Division Technical Chemicals & Products, Inc. | Transdermal delivery of the eutomer of a chiral drug |
-
1996
- 1996-09-06 US US08/706,624 patent/US5985317A/en not_active Expired - Lifetime
-
1997
- 1997-08-29 AU AU42427/97A patent/AU4242797A/en not_active Abandoned
- 1997-08-29 KR KR1019997000848A patent/KR20000068029A/ko not_active Withdrawn
- 1997-08-29 NZ NZ333866A patent/NZ333866A/xx unknown
- 1997-08-29 BR BR9712806-6A patent/BR9712806A/pt not_active Application Discontinuation
- 1997-08-29 EP EP97940709A patent/EP0952799A1/en not_active Withdrawn
- 1997-08-29 CA CA002262693A patent/CA2262693A1/en not_active Abandoned
- 1997-08-29 JP JP10512764A patent/JP2000517343A/ja not_active Withdrawn
- 1997-08-29 WO PCT/US1997/015302 patent/WO1998009591A1/en not_active Ceased
- 1997-09-01 ZA ZA9707832A patent/ZA977832B/xx unknown
- 1997-09-03 AR ARP970104009A patent/AR009516A1/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| EP0952799A1 (en) | 1999-11-03 |
| JP2000517343A (ja) | 2000-12-26 |
| NZ333866A (en) | 2000-08-25 |
| ZA977832B (en) | 1998-03-19 |
| AR009516A1 (es) | 2000-04-26 |
| US5985317A (en) | 1999-11-16 |
| KR20000068029A (ko) | 2000-11-25 |
| WO1998009591A1 (en) | 1998-03-12 |
| BR9712806A (pt) | 1999-11-23 |
| AU4242797A (en) | 1998-03-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5985317A (en) | Pressure sensitive adhesive matrix patches for transdermal delivery of salts of pharmaceutical agents | |
| US6365178B1 (en) | Method of making pressure sensitive adhesive matrix patches for transdermal drug delivery using hydrophilic salts of drugs and hydrophobic pressure sensitive adhesive dispersions | |
| AU696777B2 (en) | Triacetin as a transdermal penetration enhancer | |
| US5122383A (en) | Sorbitan esters as skin permeation enhancers | |
| CA2098196C (en) | Method and systems for administering drugs transdermally using sorbitan esters as skin permeation enhancers | |
| CA2135925C (en) | Use of glycerin in moderating transdermal drug delivery | |
| US5227169A (en) | Sorbitan esters as skin permeation enhancers | |
| AU717183B2 (en) | Fatty acid esters of lactic acid salts as permeation enhancers | |
| EP0743842B1 (en) | Drug-containing adhesive composite transdermal delivery device | |
| US5212199A (en) | Sorbitan esters as skin permeation enhancers | |
| CA2343100A1 (en) | Method of making pressure sensitive adhesive matrix patches containing hydrophilic salts of drugs | |
| JPH05279254A (ja) | クロニジン経皮投与製剤 | |
| MXPA99002039A (en) | Pressure sensitive adhesive matrix patches for transdermal delivery of salts of pharmaceutical agents | |
| JPH10120593A (ja) | 抗真菌外用剤 | |
| HK1013790B (en) | Systems for administering drugs transdermally using sorbitan esters as skin permeation enhancers | |
| HK1010679B (en) | Drug-containing adhesive composite transdermal delivery device |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| FZDE | Discontinued |